Biocon Biologics, Just - Evotec Biologics ink licensing pact for biosimilar asset

Biotechnology major Biocon and German drug firm Evotec SE on Thursday said their subsidiaries have entered into a licensing agreement for a biosimilar asset.

The agreement has been signed between Biocon Biologics and Just - Evotec Biologics.

Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes, oncology and immunology, the companies said a joint statement